ETFs
V
VTRS
Viatris Inc Ord Shs
18.26
-0.40-2.12%After Hours: 18.39 +0.13 +0.71%19:30 10/19 EDT
OPEN/PREV CLOSE18.33/18.48
TODAY RANGE17.86-18.38
VOL2.31M
MARKET CAP20.81B
52 WEEK RANGE9.58-18.75
AVG VOL (3M)9.30M
% TURNOVER0.20%
TURNOVER--
P/E (TTM)-50.7281
% RANGE2.82%
EPS(TTM)-0.3571
P/E(FORWARD)78.64
P/B1.468
BVPS12.34
DIVIDEND0.4800
P/S1.458
BETA--
DIV YIELD2.65%
FREE FLOAT MKT CAP20.74B
SHARES OUTSTANDING1.15B
NEXT EARNINGS11/04-11/09
FREE FLOAT1.15B
LOT SIZE1
EX-DATE08/21/2026
News
Press Releases
Financial Reports
Profile
Dow Jones·2d ago
Viatris Is Maintained at Neutral by JP Morgan
TipRanks·2d ago
Viatris price target raised to $20 from $18 at JPMorgan
Simply Wall St·3d ago
What Viatris Holders Bought Into Before An 83% Run
Simply Wall St·4d ago
Presbyopia Approval Might Change The Case For Investing In Viatris Stock (VTRS)
Simply Wall St·5d ago
Viatris (VTRS) Wins FDA Approval For RYZUMVI, Is The Upside Already Priced In?
Seeking Alpha·6d ago
Viatris, Opus granted FDA label expansion for Ryzumvi in presbyopia
TipRanks·10/16 16:05
Opus Genetics reports FDA approval of phentolamine ophthalmic solution 0.75%
Seeking Alpha·10/16 12:28
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
Same Industry
Name/Symbol
Change%
Price